Rosetta Genomics MDx tests available to America’s Choice Provider Network
February 1, 2016 – PRINCETON. Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into an agreement with America’s Choice Provider Network (ACPN®), an independent multispecialty national provider network, that establishes health insurance access to Rosetta’s entire suite of diagnostic tests and services.
Under the terms of the agreement, Rosetta Genomics and CynoGen, Inc. (d/b/a PersonalizeDx), a Rosetta Genomics company, are established as ACPN preferred providers, and their proprietary miRNA testing services and entire menu of diagnostic tests and services will be covered by over 1,700 payers and will be available to more than 22 million members of ACPN.
“With the addition of ACPN to our growing list of established health insurance providers, more than 150 million Americans now have access to our entire suite of high-value diagnostic tests and services. This expanded patient access is an important component to bringing our products to physicians in order to aid in diagnoses, optimize treatment decisions, enable targeted therapy selections and facilitate treatment monitoring,” noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “This agreement comes at an opportune time, as we see continued growth in collections, including a record month of nearly $1 million in collections last month, along with anticipated increases to reimbursement amounts for some of our key FISH tests,” added Mr. Berlin.
“We are delighted to have Rosetta Genomics’ high-value diagnostic tests and services available to our members nationwide. Rosetta Genomics is a leader in molecular diagnostics and this partnership highlights our commitment to include progressive, cutting-edge companies and technologies in our national provider network,” said Seth Breeden, Chief Operating Officer of ACPN.
“We are particularly pleased to expand patient access for RosettaGX Reveal, our recently-launched, first-of-its-kind microRNA classifier for indeterminate thyroid nodules. This new patient access brings the total number of covered lives for RosettaGX Reveal to over 150 million. This increased access, along with the potential health economic benefits RosettaGX Reveal can bring by avoiding unnecessary surgeries, creates prime conditions that should enhance adoption in a market opportunity valued at more than $350 million annually in the U.S. alone,” added Mr. Berlin.
Source: Rosetta Genomics